TABLE 2.
Key demographic and pharmacokinetic features of the patients providing data for the external validation data seta
| Characteristic | Value(s) |
|---|---|
| Median (IQR) age (yr) | 2.2 (1.1, 4.9) |
| No. of patients aged (yr): | |
| <2 | 20 |
| 2–12 | 19 |
| >12 | 2 |
| No. of males/no. of females | 24/17 |
| Median (IQR) total body wt (kg) | 12.4 (8.6, 21.0) |
| Median (IQR) ht (cm) | 89.0 (71.0, 112.0) |
| Median (IQR) serum creatinine concn (μmol/liter) | 29 (<30, 51) |
| Median (IQR) creatinine clearance (ml/min/1.73 m2)b | 90.6 (71.7, 112.0) |
| No. of observations | 269 |
| Median (IQR) no. of sampling occasions/patient | 6.6 (3, 11) |
| Median (IQR) dose (mg/kg) | 11.3 (9.9, 12.5) |
| Median (IQR) time of sampling after dosing (h) | 5.1 (2.1, 6) |
| Median (IQR) tobramycin concn (mg/liter) | 6.1 (2.8, 15.2) |
a
Data are for 41 patients.
b
Calculated using the modified Schwartz formula (34).